PDCD1 and cancer: Blocking the immune checkpoint receptor ‘programmed cell death-1’ (PD-1), and its ligands PD-L1 and PD-L2, is one of the most promising strategies in cancer immunotherapy.1–4 PD-L1 and PD-L2 are expressed by antigen-presenting cells such as macrophages or B-cells.